International Innovative Clinical CRO ClinChoice Completes Series E Round Financing of $150 Million, Led by Legend Capital

ClinChoice, an international innovative clinical CRO company, recently announced the successful completion of its Series E round financing with $150 million. The investment was led by Legend Capital and proceeds of the financing will be used to fund the Company's continued business expansion, M&A, and innovative service offering worldwide. ClinChoice has completed multiple rounds of financing to date and is favored by many renowned investment institutions.

Roots in China, Eye on the world. ClinChoice serves the global market by providing Integrated One-stop Service Offerings for new bio-pharmaceutical and medical device clients worldwide. ClinChoice has over 3000 employees worldwide covering most of the drug development hotbeds in the US, China, multiple countries in Europe and Southeast Asia. It has completed more than 1,000 Phase I-IV full-service clinical projects and supported over 100 innovative drug registrations, clinical design and development. With over 25 years of high-quality services, ClinChoice strictly adheres to GCP and ICH standards and has developed robust SOPs recognized by more than 50 large multinational companies, all of which have passed multiple on-site inspections by the National Medical Products Administration, the US FDA, and the EU EMA.

According to the Global Chairman and CEO of ClinChoice, Mr. Ling ZHEN, "We thank the investors for their trust in ClinChoice. This round of capital investment fully validates ClinChoice's rapid growth and future potential in the field of clinical CRO. With the new round of financing, we will further enhance our innovative service offering and continue business expansion by organic growth and M&A, in order to better serve our clients worldwide."

Dr. Hank ZHOU, Co-Chief Investment Officer of Legend Capital, said, "ClinChoice is a clinical CRO company that we continuously paid attention to, being another successful case of the multi-fund cooperation of Legend Capital. We conducted a comprehensive and in-depth investigation before investing in ClinChoice, and we were deeply impressed by the company's advantages, innovation capabilities and talented team. We are willing to work together to make ClinChoice a practitioner and leader in the clinical CRO industry. "